A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with autoimmune disease(s)
VIS171-103
Phase 1 other active
Quick answer
A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with autoimmune disease(s) for Systemic lupus erythematosus, Immune-mediated focal segmental glomerulosclerosis, Alopecia Areata is a Phase 1 program (other) at Otsuka Novel Products GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Otsuka Novel Products GmbH
- Indication
- Systemic lupus erythematosus, Immune-mediated focal segmental glomerulosclerosis, Alopecia Areata
- Phase
- Phase 1
- Modality
- other
- Status
- active